New combo therapy aims to supercharge immune system against HPV cancer
Disease control
Completed
This study tested whether adding a new immunotherapy called PDS0101 to an existing drug (pembrolizumab) could better treat advanced head and neck cancer caused by HPV16. It involved 95 adults whose cancer had returned or spread. The goal was to see if the combination could help t…
Phase: PHASE2 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC